Drug combo aims to boost lung cancer treatment
NCT ID NCT03392246
First seen Jan 11, 2026 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This phase 2 study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer who have not yet received EGFR inhibitors. The trial enrolls 25 participants and measures how well the tumors respond and how long progression is delayed. The goal is to see if the combination works better than osimertinib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
osimertinib (Tagrisso) and selumetinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced EGFR-mutant lung cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The combination may cause more side effects than osimertinib alone, and it's not yet clear if it works better than standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.